pLKO mouse shRNA 1 rictor Citations (9)
Originally described in: An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, Gray NS J Biol Chem. 2009 Mar 20. 284(12):8023-32. PubMed Journal
Articles Citing pLKO mouse shRNA 1 rictor
| Articles |
|---|
| Alcohol-induced modulation of rictor and mTORC2 activity in C2C12 myoblasts. Hong-Brown LQ, Brown CR, Navaratnarajah M, Huber DS, Lang CH. Alcohol Clin Exp Res. 2011 Aug;35(8):1445-53. doi: 10.1111/j.1530-0277.2011.01480.x. Epub 2011 Mar 25. PubMed |
| Deficiency in mTORC1-controlled C/EBPbeta-mRNA translation improves metabolic health in mice. Zidek LM, Ackermann T, Hartleben G, Eichwald S, Kortman G, Kiehntopf M, Leutz A, Sonenberg N, Wang ZQ, von Maltzahn J, Muller C, Calkhoven CF. EMBO Rep. 2015 Aug;16(8):1022-36. doi: 10.15252/embr.201439837. Epub 2015 Jun 25. PubMed |
| DEPTOR promotes survival of cervical squamous cell carcinoma cells and its silencing induces apoptosis through downregulating PI3K/AKT and by up-regulating p38 MAP kinase. Srinivas KP, Viji R, Dan VM, Sajitha IS, Prakash R, Rahul PV, Santhoshkumar TR, Lakshmi S, Pillai MR. Oncotarget. 2016 Apr 26;7(17):24154-71. doi: 10.18632/oncotarget.8131. PubMed |
| mTOR and neuronal cell cycle reentry: How impaired brain insulin signaling promotes Alzheimer's disease. Norambuena A, Wallrabe H, McMahon L, Silva A, Swanson E, Khan SS, Baerthlein D, Kodis E, Oddo S, Mandell JW, Bloom GS. Alzheimers Dement. 2016 Sep 29. pii: S1552-5260(16)32895-3. doi: 10.1016/j.jalz.2016.08.015. PubMed |
| Increased Levels of Rictor Prevent Mutant Huntingtin-Induced Neuronal Degeneration. Creus-Muncunill J, Rue L, Alcala-Vida R, Badillos-Rodriguez R, Romani-Aumedes J, Marco S, Alberch J, Perez-Otano I, Malagelada C, Perez-Navarro E. Mol Neurobiol. 2018 Oct;55(10):7728-7742. doi: 10.1007/s12035-018-0956-5. Epub 2018 Feb 19. PubMed |
| ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancer. Harwood FC, Klein Geltink RI, O'Hara BP, Cardone M, Janke L, Finkelstein D, Entin I, Paul L, Houghton PJ, Grosveld GC. Sci Adv. 2018 Sep 12;4(9):eaar3938. doi: 10.1126/sciadv.aar3938. eCollection 2018 Sep. PubMed |
| A novel lysosome-to-mitochondria signaling pathway disrupted by amyloid-beta oligomers. Norambuena A, Wallrabe H, Cao R, Wang DB, Silva A, Svindrych Z, Periasamy A, Hu S, Tanzi RE, Kim DY, Bloom GS. EMBO J. 2018 Nov 15;37(22):e100241. doi: 10.15252/embj.2018100241. Epub 2018 Oct 22. PubMed |
| Mechanism of Regulation of Big-Conductance Ca(2+)-Activated K(+) Channels by mTOR Complex 2 in Podocytes. Wang Y, Tao J, Wang M, Yang L, Ning F, Xin H, Xu X, Cai H, Zhang W, Yu K, Zhang X. Front Physiol. 2019 Feb 28;10:167. doi: 10.3389/fphys.2019.00167. eCollection 2019. PubMed |
| mTORC2 suppresses cell death induced by hypo-osmotic stress by promoting sphingomyelin transport. Ono Y, Matsuzawa K, Ikenouchi J. J Cell Biol. 2022 Apr 4;221(4):e202106160. doi: 10.1083/jcb.202106160. Epub 2022 Mar 23. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.